-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] "From January to June 2022, the operating income will be 2.
871 billion yuan, a year-on-year increase of 20.
04%, the net profit attributable to shareholders of the listed company is 299 million yuan, a year-on-year increase of 26.
74%, and the earnings per share will be 0.
5207 yuan
.
"This is the 2022 semi-annual report data disclosed by Chutian Technology, a leading domestic pharmaceutical equipment company, on August 27
.
Pharmaceutical equipment (Photo source: Pharmaceutical Network) The development of the pharmaceutical equipment industry in 2022 is still accelerating
.
In the report, Chutian Technology suggested that in 2022, the proportion of vaccine-related equipment contribution may be reduced, resulting in the risk of equity incentive performance assessment not meeting expectations; and the company's 2022 annual new order target of 10 billion, due to the epidemic.
, which may cause the risk that the annual new order target will not meet the target expectation
.
However, judging from the semi-annual report, Chutian Technology's performance in the first half of the year was remarkable
.
It can be seen from the disclosed operating conditions that the company's new orders and orders in hand at the end of the half year are sufficient.
During the reporting period, through the establishment of a holding subsidiary, Chutian Siweikang, the company has basically completed the production of stock solution preparation equipment and gene and cell therapy drugs in the front-end of biopharmaceuticals.
In the first half of the year, the R&D investment was 232 million yuan, a year-on-year increase of 17.
32%
.
With continued high R&D investment, the company plans to complete the development of 50 new products in 2022
.
In addition, the production capacity construction of Chutian Technology is also accelerating
.
The construction of the fifth phase of the project is about to be carried out.
The production capacity construction of Chutian Huatong with a production capacity of 2 billion and an area of 550 mu has also been started, and part of the construction of the first phase will be completed by the end of this year
.
Canaan Technology also disclosed its semi-annual report on August 27, which also achieved double growth in revenue and net profit, of which operating income increased by 14.
33% year-on-year, and net profit increased by 12.
63% year-on-year
.
At the same time, during the reporting period, Canaan Technology invested 31.
6448 million yuan in R&D, a year-on-year increase of 13.
58%.
The company stated that the increase in R&D investment in new products and new technologies during the reporting period resulted in an increase in R&D personnel and corresponding salaries
.
Canaan Technology is a domestic supplier of overall solutions for oral solid preparation smart factories.
A series of favorable policies have created a policy environment for the sound development of enterprises
.
During the reporting period, the company continued to innovate in technology research and development, and made more achievements in the field of intellectual property.
At the same time, the company's ability to provide equipment for the entire line and brand advantages were outstanding, coupled with a sound product system, in-depth service concepts throughout the chain, and three-dimensional marketing.
System, the company has the strength of import substitution, opening up a situation for further development
.
Earlier, the performance forecast released by Tofflon on the evening of July 11 showed that the net profit attributable to the parent in the first half of the year was expected to be 391 million yuan to 425 million yuan, a year-on-year increase of 15%-25%
.
The company expects to disclose the 2022 interim report on 2022-08-30
.
On the whole, the above-mentioned leading pharmaceutical equipment companies that have disclosed semi-annual reports or performance forecasts have achieved performance growth, and the overall development of the industry is still accelerating
.
Leading enterprises are expected to usher in opportunities It is generally believed in the industry that the entire environment of the pharmaceutical equipment industry, including market demand, policies and other factors, is improving, and leading enterprises are expected to usher in opportunities
.
For example, Galaxy Securities once pointed out in a research report that combining the perspectives of policy, fundamentals and asset allocation, pharmaceutical equipment in the pharmaceutical field may perform better, because the policy immunization sector in medicine is mainly concentrated in the upstream, and pharmaceutical equipment is in the this field
.
CITIC Securities also mentioned in the research report that the global pharmaceutical equipment industry is constantly iterating with the advancement of downstream treatment technologies.
Emerging technologies represented by cell gene therapy and multispecific drugs have great commercialization potential and are expected to drive global upstream demand for biological drugs.
Rapid expansion has catalyzed the further transformation of leading enterprises into integrated full-process service providers
.
Combined with the performance of leading pharmaceutical equipment companies in the first half of the year, actions such as increasing the layout of emerging fields such as biopharmaceuticals, increasing new product development, strengthening R&D investment, and expanding production capacity are frequent actions.
It can be seen that leading companies are seizing new opportunities in the industry.
Overweight layout, in order to be able to seize more markets
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
871 billion yuan, a year-on-year increase of 20.
04%, the net profit attributable to shareholders of the listed company is 299 million yuan, a year-on-year increase of 26.
74%, and the earnings per share will be 0.
5207 yuan
.
"This is the 2022 semi-annual report data disclosed by Chutian Technology, a leading domestic pharmaceutical equipment company, on August 27
.
Pharmaceutical equipment (Photo source: Pharmaceutical Network) The development of the pharmaceutical equipment industry in 2022 is still accelerating
.
In the report, Chutian Technology suggested that in 2022, the proportion of vaccine-related equipment contribution may be reduced, resulting in the risk of equity incentive performance assessment not meeting expectations; and the company's 2022 annual new order target of 10 billion, due to the epidemic.
, which may cause the risk that the annual new order target will not meet the target expectation
.
However, judging from the semi-annual report, Chutian Technology's performance in the first half of the year was remarkable
.
It can be seen from the disclosed operating conditions that the company's new orders and orders in hand at the end of the half year are sufficient.
During the reporting period, through the establishment of a holding subsidiary, Chutian Siweikang, the company has basically completed the production of stock solution preparation equipment and gene and cell therapy drugs in the front-end of biopharmaceuticals.
In the first half of the year, the R&D investment was 232 million yuan, a year-on-year increase of 17.
32%
.
With continued high R&D investment, the company plans to complete the development of 50 new products in 2022
.
In addition, the production capacity construction of Chutian Technology is also accelerating
.
The construction of the fifth phase of the project is about to be carried out.
The production capacity construction of Chutian Huatong with a production capacity of 2 billion and an area of 550 mu has also been started, and part of the construction of the first phase will be completed by the end of this year
.
Canaan Technology also disclosed its semi-annual report on August 27, which also achieved double growth in revenue and net profit, of which operating income increased by 14.
33% year-on-year, and net profit increased by 12.
63% year-on-year
.
At the same time, during the reporting period, Canaan Technology invested 31.
6448 million yuan in R&D, a year-on-year increase of 13.
58%.
The company stated that the increase in R&D investment in new products and new technologies during the reporting period resulted in an increase in R&D personnel and corresponding salaries
.
Canaan Technology is a domestic supplier of overall solutions for oral solid preparation smart factories.
A series of favorable policies have created a policy environment for the sound development of enterprises
.
During the reporting period, the company continued to innovate in technology research and development, and made more achievements in the field of intellectual property.
At the same time, the company's ability to provide equipment for the entire line and brand advantages were outstanding, coupled with a sound product system, in-depth service concepts throughout the chain, and three-dimensional marketing.
System, the company has the strength of import substitution, opening up a situation for further development
.
Earlier, the performance forecast released by Tofflon on the evening of July 11 showed that the net profit attributable to the parent in the first half of the year was expected to be 391 million yuan to 425 million yuan, a year-on-year increase of 15%-25%
.
The company expects to disclose the 2022 interim report on 2022-08-30
.
On the whole, the above-mentioned leading pharmaceutical equipment companies that have disclosed semi-annual reports or performance forecasts have achieved performance growth, and the overall development of the industry is still accelerating
.
Leading enterprises are expected to usher in opportunities It is generally believed in the industry that the entire environment of the pharmaceutical equipment industry, including market demand, policies and other factors, is improving, and leading enterprises are expected to usher in opportunities
.
For example, Galaxy Securities once pointed out in a research report that combining the perspectives of policy, fundamentals and asset allocation, pharmaceutical equipment in the pharmaceutical field may perform better, because the policy immunization sector in medicine is mainly concentrated in the upstream, and pharmaceutical equipment is in the this field
.
CITIC Securities also mentioned in the research report that the global pharmaceutical equipment industry is constantly iterating with the advancement of downstream treatment technologies.
Emerging technologies represented by cell gene therapy and multispecific drugs have great commercialization potential and are expected to drive global upstream demand for biological drugs.
Rapid expansion has catalyzed the further transformation of leading enterprises into integrated full-process service providers
.
Combined with the performance of leading pharmaceutical equipment companies in the first half of the year, actions such as increasing the layout of emerging fields such as biopharmaceuticals, increasing new product development, strengthening R&D investment, and expanding production capacity are frequent actions.
It can be seen that leading companies are seizing new opportunities in the industry.
Overweight layout, in order to be able to seize more markets
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
